Stock Notes

Gujarat Themis Biosyn

Every Finvezto stock note on Gujarat Themis Biosyn, dated and newest first. Coverage spans pharma api.

1 note and counting
11 Sep 2026
Gujarat Themis Biosyn approved raising up to Rs 585 crore of non-convertible debentures on a private placement basis.
It follows a Rs 750 crore QIP completed on 28 August, so about Rs 1,335 crore has been lined up against FY26 revenue of roughly Rs 166 crore.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.